Pharmascience, Inc.

Chronic hypoparathyroidism is a rare endocrine disorder characterised by low or inadequate levels of PTH. Credit: Pixel-Shot / Shutterstock. Pharmascience unit Pendopharm has entered an exclusive distribution agreement with Ascendis Pharma to bring the hypoparathyroidism treatment TransCon PTH (palopegteriparatide) to the Canadian market. Pendopharm will be responsible for securing regulatory approval and overseeing the commercialisation of the product in the country. Neither companies has disclosed the financial terms of the deal. Ascendis Pharma executive vice-president and chief commercial officer Camilla Harder Hartvig stated: “We are delighted to partner with Pendopharm to bring TransCon PTH to Canada, contributing to our shared goal of making a meaningful difference in the lives of patients living with chronic hypoparathyroidism.” A parathyroid hormone (PTH) replacement therapy, TransCon PTH is aimed at treating chronic hypoparathyroidism, a rare endocrine disorder characterised by low or inadequate levels of PTH. See Also: HF-158K1 by HighField Biopharmaceuticals for Bladder Cancer: Likelihood of Approval Innovent sells its share in CAR T-cell therapy to IASO Bio for 18% equity The therapy has already secured approval in the European Union, the European Economic Area and Great Britain under the brand name YORVIPATH, specifically for adult patients. TransCon PTH is undergoing development for the same indication in the US, Japan and other international markets. Pendopharm vice-president and GM Jad Isber stated: “This partnership represents Pendopharm’s commitment to bringing innovative medicines that address unmet medical needs to Canadian patients. “We look forward to working with Canadian endocrinologists to make TransCon PTH available to all patients who may benefit from it.” In May 2024, Pendopharm announced the renewal of a distribution agreement with Anika Therapeutics for Cingal, Monovisc and Orthovisc up to 2030.

Sean will drive the Company through its next phase of growth and bring its highly promising pipeline through clinical development He brings more than 20 years of senior executive experience in the life science industry across business development, operations, and strategy STRASBOURG, France & MONTREAL & BOSTON--(BUSINESS WIRE)-- Domain Therapeutics a global clinical-stage biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the appointment of Sean A. MacDonald as its Chief Executive Officer (CEO). This press release features multimedia. View the full release here: Sean Mc Donald, CEO Domain Therapeutics (Photo: Business Wire) Sean, formerly Executive Strategic Advisor and most recently Chief Business Officer of Domain Therapeutics, has played a pivotal role over the past year in defining, alongside Domain’s management team, both corporate and clinical strategy. His efforts have been instrumental in positioning the development stage assets of Domain’s proprietary portfolio of GPCR-targeting immunotherapies. Sean’s in-depth knowledge and experience within all aspects of Domain’s operations, will be invaluable in driving the Company’s next phase of growth, leading and executing the Series B fundraising. As he steps into his new role as CEO, he will continue to pave the way for Domain towards maturing into a global clinical company. His leadership will be crucial in advancing and expanding Domain’s innovative portfolio of pioneering anticancer candidates. Sean has a proven international track record of success in strategy and business development in several executive positions in the pharmaceutical industry (iOnctura, Cosmo Pharmaceuticals, Corbin Therapeutics Inc, Pharmascience Inc.), leading and closing multiple deals, including mergers and acquisitions, critical investments, fundraising and licensing activities, whilst building successful biotech companies in North America and Europe. In addition, he currently serves as a Board Director at Edesa Biotech. Laurence Rulleau, Chair of the Board of Directors of Domain Therapeutics, said: “Sean’s profound understanding of Domain and strategic and operational expertise, executing deals at the most senior levels of business development and planning, makes him ideal to be at the operative helm of the Company as CEO. The Board’s unanimous decision ensures Domain is in a solid position to maximise its strong growth prospects. I am confident that this new leadership will drive Domain’s evolution as a global cancer company and move the Company forward towards even greater success to the benefit of cancer patients and their families. Sean succeeds Anthony Johnson, who I’d like to thank for his support of the Company. Sean A. MacDonald, Chief Executive Officer of Domain Therapeutics, commented: “2024 is set to be a pivotal year for the Company and I am honoured to have been given the opportunity to lead and support the tremendous talent at Domain. Over the past several months, I have witnessed first-hand the remarkable strength of our team and the exceptional science we are developing. I look forward to continuing to drive our programs forward through the clinic and bring better and more effective treatment options to cancer patients worldwide.” About Domain Therapeutics :

Montreal, Quebec--(News - April 3, 2024) - Pharmascience Inc., the largest Canadian-owned pharmaceutical company and a leader in the Canadian generic market, will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 16 and 17 at the Metro Toronto Convention Centre. Dates: Tuesday April 16, 2024-Wednesday April 17, 2024 Time: 8:30 AM - 5:00 PM ET Location: Metro Toronto Convention Centre, North Building 255 Front St W Toronto, Ontario M5V 2W6 Martin Arès, CEO will be speaking at 9:30am ET on April 17th. Interested parties can register to attend here. Members of the Pharmascience Inc. management team will also be taking meetings throughout the day. To register for the 2024 Bloom Burton & Co. Healthcare Investor Conference, please follow this link. About Pharmascience Inc. Founded in 1983, Pharmascience Inc. is the largest Canadian-owned pharmaceutical company, with 1,600 employees proudly headquartered in Montreal. It is a full-service privately-owned organization with strong roots in Canada and a growing global reach with product distribution in over 50 countries. Ranked 52nd among Canada’s top 100 Research and Development (R&D) investors in 2023, with more than $50 million invested each year, Pharmascience Inc. is among the largest drug manufacturers in Canada. About the Conference: The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings. About Bloom Burton & Co.: Bloom Burton & Co. is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies. Bloom Burton has an experienced team of medical, scientific, industry and capital markets professionals who perform a deep level of diligence, which combined with our creative and entrepreneurial approach, assists our clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, strategic advisory, as well as company creation and incubation services. Bloom Burton Securities Inc. is a member of the Canadian Investment Regulatory Organization (CIRO) and is also a member of the Canadian Investor Protection Fund (CIPF). For questions and further information please contact: Paul J. Evans Vice President, Global Business Development & Portfolio +1-215-431-5022 pevans1@pharmascience.com